X-ZELL technology on show at SWITCH X SSF 2019
Singapore, October 2019 – X-ZELL has been selected as one of the start-ups to be featured on A*ccelerate Technologies’ Innovation Pavilion at the upcoming SWITCH exhibition in Singapore.
Short for Singapore Week of Innovation and Technology, SWITCH first came to life in 2018 as a platform to showcase Singapore’s vibrant entrepreneurial and technology innovation ecosystem.
In 2019, the landmark event – comprising of a conference, exhibition as well as a series of industry and innovation events – will be held in conjunction with the Singapore FinTech Festival (SFF), one of the largest financial technology summits in the world.
The move is expected to create synergies across a broad spectrum of sectors ranging from Advanced Manufacturing & Engineering, Urban Solutions & Sustainability, Health & Biomedical Sciences and Services & Digital Economy through to FinTech.
In 2018, the two events drew close to 57,000 delegates from almost 130 countries in 2018.
A*ccelerate Technologies – the commercialisation arm of the Agency for Science, Technology and Research (A*STAR) – will make full use of the combined potential by presenting some of the nation’s most promising innovators on a joint stand at the heart of the exhibition area.
X-ZELL, which has been partnering with A*ccelerate Technologies’ Diagnostics Development (DxD) Hub since December 2018, has been selected as one of them.
Ranked among Asia’s 50 most innovative health tech start-ups for two years running, the Singapore-based company is fusing next-generation cell detection technology with cutting-edge AI to detect traces of early-stage cancer in small, 10mL blood samples.
Date: 11-13 Nov 2019
Venue: Singapore Expo
Booth: 5K 17
Head of Strategy, Marketing & Communications
+65 9630 0706
Recurrently ranked among the most innovative health technology start-ups in Asia, X-ZELL is fusing next-generation cell detection technology with cutting-edge Artificial Intelligence to isolate and visualise ultra-rare cells in blood and frozen tissue. Established in Bangkok, Thailand, the company recently made global headlines when it demonstrated the ability to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in small, 10mL blood samples. Widely considered one of the most promising biomarkers for the early detection of clinically significant cancers, tCEC had previously been classified as undetectable in clinical routine. Now headquartered in Singapore, X-ZELL is aiming to make tCEC-based cancer screening accessible to patients around the globe – making the young company one of the promising names in the booming cancer prevention space.